Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
176 hedge funds and large institutions have $2.17B invested in Spark Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 65 increasing their positions, 53 reducing their positions, and 23 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 53
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
2% more funds holding
Funds holding: 172 → 176 (+4)
23% less call options, than puts
Call options by funds: $8.35M | Put options by funds: $10.9M
33% less capital invested
Capital invested by funds: $3.23B → $2.17B (-$1.07B)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$110M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$57.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$20.8M |
| 4 |
CC
Casdin Capital
New York
|
+$14.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$74.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$50.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$33.2M |
| 4 |
Janus Henderson Group
London,
|
-$23.3M |
| 5 |
Morgan Stanley
New York
|
-$20.8M |
ONCE Hedge Fund Activity: Q3 2018 in Review
176 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q3 2018, worth a combined $2.17B — down 33% from $3.23B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ONCE positions and 23 closed out — a net gain of 4 holders — while 65 added to existing stakes and 53 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $110M. The largest seller was Lord, Abbett & Co, cutting an estimated $74.9M.
- 176 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q3 2018, up from 172 in Q2 2018.
- Funds reported $2.17B of Spark Therapeutics, Inc. Common Stock stock for Q3 2018, down 33% quarter-over-quarter.
- 27 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q3 2018 and 23 closed out, a net change of +4 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q3 2018 was Wellington Management Group, an estimated $110M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q3 2018 was Lord, Abbett & Co, an estimated $74.9M sold.
Based on aggregated 13F filings for Q3 2018.